UNSPSC 51272602: Phenoperidine

This classification denotes an opioid and analgesic agent with the molecular formula C23H29NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G9BH09J4JW, chemically known as 4-piperidinecarboxylic acid, 1-(3-hydroxy-3-phenylpropyl)-4-phenyl-, ethyl ester but generally known as phenoperidine, which bears US NIH Compound Identifier 11226. European Medicines Agency schedules Phenoperidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09775MIG.

UNSPSC 51272602 Phenoperidine is a Commodity code that covers specialized pharmaceutical products and related drug-management systems procured by state and local health agencies. Recent state and local solicitations under this code reflect procurement of naloxone and drug deactivation systems for public health and emergency-response initiatives, as well as broader generic pharmaceuticals and over-the-counter products distributed through state cooperative purchasing frameworks. The issuing bodies span state health departments, county health agencies, and state cooperative purchasing alliances that aggregate demand across multiple jurisdictions. Work being solicited includes annual supply contracts for naloxone and drug safety systems with quarterly delivery schedules, participation in multistate cooperative pharmaceutical frameworks with manufacturer direct-contracting components, and information-gathering phases to explore therapeutic pharmacy initiatives that bypass traditional pharmacy benefit manager intermediaries.

Recent activity concentrates in Florida and Minnesota, with cross-state participation through cooperative vehicles. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually on a two-year contract with one-year renewal option, with a response deadline of July 26, 2023 and quarterly deliveries to the Seminole County Community Health Building in Sanford. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products across participating state and local facilities including Oregon, with proposals due March 26, 2026 and contract effectiveness scheduled for July 1, 2026; the RFP requires vendor relationships with three authorized wholesalers and compliance with current Good Manufacturing Practices and Drug Supply Chain Security Act standards. Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to solicit vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, indicating preliminary market research before formal competitive solicitation.